FAP Knockout Cell Line (HEK 293)

The choice depends on whether you are studying FAP (fibroblast activation protein, FAPα, seprase)'s role as a serine protease expressed on cancer-associated fibroblasts (CAFs) or modeling its applications in PET imaging and emerging FAP-targeted radioligand therapy. The Knockout line is the standard tool for asking whether FAP is required for these processes — FAP is a type II transmembrane serine protease (dipeptidyl peptidase activity, endopeptidase activity for gelatin/collagen) selectively expressed on CAFs in tumor stroma but minimally expressed in normal adult tissues; FAP is one of the most prominent emerging targets in cancer PET imaging, with 68Ga-FAPI (FAP-inhibitor) tracers showing superior tumor-to-background contrast compared to 18F-FDG in many cancers. Overexpression is useful for studying FAP in heterologous expression contexts. For cancer imaging and FAP-targeted therapy research, the EDITGENE FAP Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies of FAP and serves as a critical specificity control for FAP-targeted compound development. Rescue with wild-type or catalytically-dead FAP enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ 68Ga-FAPI-04, 68Ga-FAPI-46 (PET imaging tracers in widespread clinical use), Lu-177-FAPI radioligand therapy candidates, and emerging FAP-targeted therapeutic approaches (FAP-targeted CAR-T, anti-FAP antibodies). FAP-targeted PET imaging is considered one of the most significant advances in oncology imaging since 18F-FDG.

Primary applications: • FAP enzymatic activity: dipeptidyl peptidase and endopeptidase activity assays in FAP-null cells. • FAPI tracer specificity: critical genetic control for ⭐⭐ 68Ga-FAPI-04 and 68Ga-FAPI-46 PET imaging tracers — these tracers should have no binding/uptake in FAP-null cells. • Cancer-associated fibroblast biology: in heterologous CAF-relevant contexts, characterization of FAP-mediated stromal protease activity. • FAP-targeted radioligand therapy: Lu-177-FAPI-04 and emerging FAP-targeted radioligand therapy specificity testing. EDITGENE recommends this model as the gold-standard genetic specificity control for FAP-targeted PET imaging and emerging FAP radioligand therapy — FAP-targeted PET represents one of the most significant advances in oncology imaging.

Yes. FAP rescue experiments are well-established for FAP-targeted compound research: • Construct design: use a codon-modified FAP sequence with a small intracellular N-terminal tag (FLAG, HA) — FAP is a type II transmembrane protein with short intracellular N-terminus, single transmembrane span, and large extracellular catalytic domain; N-terminal tag preserves catalytic domain integrity. • Surface localization validation: confirm plasma membrane localization by cell surface staining before FAPI tracer testing. • Catalytically-dead rescue: S624A (catalytic serine, active site) or H734A mutations abolish protease activity. • FAPI binding studies: rescue with WT FAP restores 68Ga-FAPI tracer binding and uptake — gold-standard specificity control for PET imaging tracer validation. • Functional readout: rescue should restore FAP enzymatic activity and FAPI tracer cellular accumulation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.